Questions to be answered now....not in seven weeks time, page-8

Questions so far

Accountability is an important part of business practice and culture, and so i ask, who has been called to account, and by whom, for the following failures:-

1 Failure to obtain FDA approval of Vivagel, given that early advice to the market made approval appear a certainty.

2 Failure to have in place all the regulatory approvals for the UK Viraleze sales campaign with the result that the entire UK sales program for Viraleze has had to be abandoned.

3 Allowing material to be published that TGA could take objection to and issue a fine of $$$ for.
DEP
1. What are the preliminary results from the DEP docetaxel + gemcitabine trial for pancreatic cancer? How many have been treated? What results have been seen when used as 1st line treatment? It has been over a year since the trial commenced and to date no results have been announced.
2. The company has suggested that commercial deals could very well be signed before completion of Phase 2 trials for ? DEP irinotecan. Why has no deal been signed? The company has said results are encouraging..Why the gap between "encouraging" and no commercial agreement?
3.

SPL7013
1. Why have trials for SPL 7013 as eye drops for viral infections not been done?
2. Why have phase 2 and 3 trials not been run for Viraleze?
3. Specifically, why has the company insisted on not changing the packaging of Viraleze in the UK unless forced to? Why is some unknown principle more important than (1) contributing to the health of the general public, and (2) what is this principle that is so important so as to damage shareholder value?
4. Why has no commercial agreement been signed in India for the distribution of Viraleze? The company suggested that this was imminent.

AstraZeneca
1. Why have no more agreements been signed to proceed to clinical trials? And please, don't say it is up to AZ. Sure, but are the results truly compelling?

Remuneration
1. Are the CEO and the VP for Business Development willing to only be compensated as a function of actual share price? Are they willing to take no further compensation until share price reaches ?? say $5.00?
2. Is the BOD willing to totally change the approach to performance rights? The granting of performance rights for "progress" that never leads to actual commercialization has only served to enrich management at the expense of shareholder value. An exception to this would be the VP of Research.
3. Is the BOD willing to take no further compensation until there is true commercial success. All the qualifications listed have not resulted in profitability.

My question: WTF is going on with TGA? WTF can't an Australian company step foot inside its own backyard. Has the INCOMPETENT Jackie Fairley & co tried knocking on the front door! Is their any relationship with the TGA? WTF is that relationship? Why does Jackie Fairley not communicate with shareholders? SPL is not an emotion Jackie Fairley, stop treating SPL as if it is yourself and start realizing that SPL is a business that requires you to be transparent to Australian shareholders of where the TGA is at. SPL is proudly listed on the ASX, SPL shareholders and every single business minded person in Australia is ashamed of the current Australian CEO and management!